Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.33 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.31 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.31 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.31 |
| ▸ | PLG | P00747 | 1/20 | 0.31 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.30 |
| ▸ | GABRP | O00591 | 1/20 | 0.30 |
| ▸ | GABRD | O14764 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.30 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.30 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.30 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.30 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.30 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.30 |
| ▸ | GABRE | P78334 | 1/20 | 0.30 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20758934 | 0.89 | MAP3K14 (0.32) | MAP3K14CRBN | |
| SCHEMBL20758331 | 0.87 | CCR5 (0.32) | MAP3K14 | |
| SCHEMBL797262 | 0.86 | MAP3K14 (0.33) | MAP3K14CRBNMAPTTHRBGABRA1 | |
| SCHEMBL26984265 | 0.85 | — | — | |
| SCHEMBL7214892 | 0.81 | MAP3K14 (0.36) | MAP3K14MAPTMTNR1ATSHR | |
| SCHEMBL7217095 | 0.81 | ALDH1A1 (0.40) | MAP3K14MAPTMTNR1A | |
| SCHEMBL2380603 | 0.79 | ALDH1A1 (0.38) | MAP3K14MAPTMTNR1A | |
| SCHEMBL10053970 | 0.78 | CCR5 (0.47) | MAP3K14CRBNMTNR1ATSHR | |
| SCHEMBL7794999 | 0.78 | — | — | |
| SCHEMBL25175873 | 0.77 | SLC6A1 (0.35) | MAP3K14MAPTTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250115571-A1 | OXOPIPERAZINE DERIVATIVES | Inthera Bioscience AG (CH) | 2025-04-10 | — | — | US | disclosed |
| US-12012393-B2 | Oxopiperazine derivatives | Inthera Bioscience AG (CH) | 2024-06-18 | — | — | US | disclosed |
| EP-3724178-B1 | 1-(PIPERIDINOCARBONYLMETHYL)-2-OXOPIPERAZINE DERIVATIVES FOR TREATING CANCER | Inthera Bioscience AG (CH) | 2024-05-01 | — | — | EP | disclosed |
| CN-115551841-A | Azetidin-3-ylcarbinol derivatives as modulators of the CCR6 receptor | 爱杜西亚药品有限公司 | 2022-12-30 | — | — | CN | disclosed |
| US-20220213057-A1 | OXOPIPERAZINE DERIVATIVES | Inthera Bioscience AG (CH) | 2022-07-07 | — | — | US | disclosed |
| US-11306068-B2 | Oxopiperazine derivatives | Inthera Bioscience AG (CH) | 2022-04-19 | — | — | US | disclosed |
| US-20200308139-A1 | OXOPIPERAZINE DERIVATIVES | Inthera Bioscience AG (CH) | 2020-10-01 | — | — | US | disclosed |
| US-10710975-B2 | Oxopiperazine derivatives | Inthera Bioscience AG (CH) | 2020-07-14 | — | — | US | disclosed |
| US-20190185449-A1 | OXOPIPERAZINE DERIVATIVES | Inthera Bioscience AG (CH) | 2019-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220213057-A1 | OXOPIPERAZINE DERIVATIVES | CYP3A5, AQP1, AVPR2 | MAP3K14 3138/4885CRBN 4270/4885MAPT 2962/4885 |
| US-11306068-B2 | Oxopiperazine derivatives | CYP3A5, AQP1, AVPR2 | MAP3K14 3138/4885CRBN 4270/4885MAPT 2962/4885 |
| US-10710975-B2 | Oxopiperazine derivatives | CYP3A5, AQP1, AVPR2 | MAP3K14 3138/4885CRBN 4270/4885MAPT 2962/4885 |
| US-20190185449-A1 | OXOPIPERAZINE DERIVATIVES | CYP3A5, AQP1, AVPR2 | MAP3K14 3138/4885CRBN 4270/4885MAPT 2962/4885 |
| US-20250115571-A1 | OXOPIPERAZINE DERIVATIVES | CYP3A5, AQP1, AVPR2 | MAP3K14 3138/4885CRBN 4270/4885MAPT 2962/4885 |
| US-20200308139-A1 | OXOPIPERAZINE DERIVATIVES | CYP3A5, AQP1, AVPR2 | MAP3K14 3138/4885CRBN 4270/4885MAPT 2962/4885 |
| US-12012393-B2 | Oxopiperazine derivatives | CYP3A5, AQP1, AVPR2 | MAP3K14 3138/4885CRBN 4270/4885MAPT 2962/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.